Laurus Labs Limited

Laurus Labs Q3 FY26 Earnings Call Transcript Released

Laurus Labs Q3 FY26 earnings call transcript released on January 23, 2026. Revenues stood at ₹1,778 crore with EBITDA margins over 27%. Significant CAPEX in peptide and ADC/gene therapy labs. Generics grew 37% to ₹1,327 crore. 9-month revenue reached ₹5,001 crore.

Laurus Labs Announces Q3 FY25 Unaudited Financial Results

Laurus Labs Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The results were approved by the Board of Directors on January 23, 2026, and published on January 24, 2026.

Laurus Labs: Q3 FY26 Results Conference Call Audio Recording Available

Laurus Labs released the audio recording for its Q3 FY26 results conference call, hosted on January 23, 2026. This update is in compliance with SEBI regulations.

Laurus Labs Q3 FY26 Revenue Jumps 26% to ₹1,778 Cr, Net Profit Up 174%

Laurus Labs reported Q3 FY26 revenues of ₹1,778 crore (up 26% YoY) and net profit of ₹252 crore (up 174% YoY). For 9M FY26, revenues were ₹5,001 crore (up 30% YoY) and net profit was ₹610 crore (up 388% YoY). EBITDA margins improved significantly to 27.3% in Q3 and 26.1% for 9M. The company confirmed its full-year outlook for strong revenue growth and margin improvement.

Laurus Labs Q3 FY26: Revenue ₹1,778 Cr, Profit ₹252 Cr; 9M Revenue ₹5,001 Cr

Laurus Labs reported Q3 FY26 revenue of ₹1,778 Cr (up 26% YoY) and net profit of ₹252 Cr (up 174% YoY). For 9M FY26, revenue reached ₹5,001 Cr (up 30% YoY) and net profit was ₹610 Cr (up 388% YoY). EBITDA margins improved significantly for both periods. The company is investing in manufacturing expansion and advanced modalities.

Laurus Labs Q3 FY26 Results: Revenue at ₹1,784 Crore, Profit ₹251.88 Crore

Laurus Labs reported consolidated revenue of ₹1,784 crore for Q3 FY26, with a net profit of ₹251.88 crore. For the nine-month period, consolidated revenue was ₹5,554 crore and net profit was ₹607.94 crore. Standalone net profit for Q3 FY26 was ₹175.08 crore.

Laurus Labs Grants 423,125 Stock Options Across Three Schemes

Laurus Labs granted 423,125 stock options across three schemes to 1,194 employees. The grant price is ₹754.50 per option, effective July 1, 2025. Vesting occurs over 2-5 years, with exercise within one year of vesting. Options are part of employee motivation and performance participation.

Laurus Labs Schedules Q3 & 9M FY26 Earnings Conference Call for Jan 23, 2026

Laurus Labs will host its Q3 & 9M FY26 earnings conference call on January 23, 2026, at 5:00 PM IST. The call will cover financial results and include an interactive Q&A session. Dial-in details are available for participants.

Laurus Labs Files Certificate Under SEBI Regulations for Q3 FY26

Laurus Labs Limited filed a certificate under SEBI (Depositories and Participants) Regulations, 2018. This filing pertains to the quarter ended December 31, 2025, confirming details of securities dematerialization and rematerialization. The certificate was issued by KFin Technologies Limited, the company's Registrar and Share Transfer Agent.

Laurus Labs: Trading Window Closed Jan 01, 2026 for Q3 FY26 Results

Laurus Labs will close its trading window from January 01, 2026. The window will reopen 48 hours after the declaration of un-audited standalone and consolidated financial results for the quarter and nine-months ending December 31, 2025. The board meeting date for results approval will be announced later.

Laurus Labs Invests ₹35 Crore in Subsidiary Laurus Bio, Stake Rises to 75.61%

Laurus Labs invested ₹34.99 crore in its subsidiary, Laurus Bio. The company acquired 13,487 preference shares, increasing its stake to 75.61% on a fully diluted basis.

Laurus Labs Invests ₹49 Crore in KRKA Pharma Rights Issue

Laurus Labs invested ₹49 crore in its joint venture, KRKA Pharma, through a rights issue. The company acquired 49 million equity shares of KRKA Pharma, each with a face value of ₹10.

Laurus Labs to Participate in B&K 360 One Investor Meet on Dec 17, 2025

Laurus Labs will participate in the B&K 360 One Investors Meet in Hyderabad on December 17, 2025. The meeting will be conducted in-person. No Unpublished Price Sensitive Information will be shared during the event.

Laurus Labs to attend J.P. Morgan India Emerging Opportunities Forum

Laurus Labs will participate in the J.P. Morgan India Emerging Opportunities Forum on 27 November 2025 in Hyderabad via virtual group meetings. The meeting date is subject to change.

Laurus Labs to participate in Avendus Spark and Citi India Investor Conferences in November 2025

Laurus Labs will participate in investor conferences with Avendus Spark on November 17, 2025, and Citi India on November 26, 2025, holding in-person meetings.

Newspaper Publication: Submission of TDS Documents for Interim Dividend

Laurus Labs published a newspaper advertisement on 1 November 2025, regarding the submission of TDS-related documents for the interim dividend for FY 2025-26 in Business Standard and Prajasakti.

Laurus Labs Q2 FY26 Earnings Conference Call Transcript

Laurus Labs' Q2 FY26 revenues reached ₹1,653 crore, with CDMO at ₹471 crore. EBITDA margins expanded to 26%. The company plans a ₹4,800 crore investment in Vizag and anticipates ARV sales around ₹2,500 crore.

Laurus Labs announces newspaper publication of Q2 & H1 FY26 financial results

Laurus Labs published financial results for the quarter and half-year ended September 30, 2025, in Business Standard and Prajasakti on October 24, 2025.

Laurus Labs releases audio recording of Q2 FY26 results conference call

Laurus Labs announced the release of the audio recording for its Q2 FY26 results conference call, which was held on October 23, 2025.

Laurus Labs Announces Q2 & H1 FY26 Results

Laurus Labs announces strong Q2 & H1 FY26 results with revenue growth of 35% and 33% respectively. EBITDA margins improved significantly. Interim dividend declared. Concall scheduled for October 23, 2025.

Laurus Labs Investor Presentation on Q2 & H1 FY26 Results

Laurus Labs announces investor presentation for Q2 & H1 FY26 results on October 23, 2025, with significant revenue growth and strategic investments in manufacturing and R&D.

Laurus Labs approves ₹0.80 interim dividend for FY26; Record Date Oct 31

Laurus Labs approved an interim dividend of ₹0.80 per share for FY26. October 31, 2025, is the Record Date, with payment on or after November 12, 2025.

Laurus Labs Approves Interim Dividend of ₹0.80 Per Share

Laurus Labs board approves unaudited financial results for the quarter ended September 30, 2025, and declares an interim dividend of ₹0.80 per share. Record date is October 31, 2025, and payment will be on or after November 12, 2025.

Laurus Labs Q2 & H1 FY26 Earnings Conference Call Invite

Laurus Labs announces a conference call on October 23, 2025, at 5:00 PM IST to discuss Q2 & H1 FY26 results. The call will be hosted by DAM Capital Advisors.

Certificate under SEBI Regulations for Quarter Ended September 30, 2025

Laurus Labs submits certificate under SEBI Regulations for the quarter ended September 30, 2025, confirming the dematerialization/rematerialization of securities details have been furnished to stock exchanges.

Laurus Labs Reports Strong Q1 FY26 Performance, Driven by CDMO & Generics Growth, Advances Strategic Investments

Laurus Labs to participate in investor conferences in Sept 2025

Laurus Labs Submits Scheme of Arrangement for Wholly Owned Subsidiary Merger

Laurus Labs to participate in Motilal Oswal Investor Conference in September 2025

Laurus Labs approves Composite Scheme of Arrangement

Laurus Labs secures 531.77 acres in Andhra Pradesh for Pharma Zone with ₹5,630 crore investment plan

Laurus Labs: Newspaper Publication of Financial Results for Quarter Ended June 30, 2025

Laurus Labs Reports Strong Q1 FY26 Performance with 31% Revenue Growth Driven by CDMO and FDF

Laurus Labs to Invest Up to EURO 5 Million in Joint Venture KRKA Pharma for New Manufacturing Facility